MX2023013385A - Genomas y vectores virales recombinantes que codifican tert. - Google Patents
Genomas y vectores virales recombinantes que codifican tert.Info
- Publication number
- MX2023013385A MX2023013385A MX2023013385A MX2023013385A MX2023013385A MX 2023013385 A MX2023013385 A MX 2023013385A MX 2023013385 A MX2023013385 A MX 2023013385A MX 2023013385 A MX2023013385 A MX 2023013385A MX 2023013385 A MX2023013385 A MX 2023013385A
- Authority
- MX
- Mexico
- Prior art keywords
- tert
- genomes
- encode
- viral vectors
- recombinant viral
- Prior art date
Links
- 239000013603 viral vector Substances 0.000 title 1
- 108010017842 Telomerase Proteins 0.000 abstract 2
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 abstract 2
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 210000003411 telomere Anatomy 0.000 abstract 1
- 102000055501 telomere Human genes 0.000 abstract 1
- 108091035539 telomere Proteins 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382441.0A EP4089171A1 (en) | 2021-05-12 | 2021-05-12 | Recombinant tert-encoding viral genomes and vectors |
| PCT/EP2022/062990 WO2022238557A1 (en) | 2021-05-12 | 2022-05-12 | Recombinant tert-encoding viral genomes and vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013385A true MX2023013385A (es) | 2024-02-06 |
Family
ID=75919286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013385A MX2023013385A (es) | 2021-05-12 | 2022-05-12 | Genomas y vectores virales recombinantes que codifican tert. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20250099618A1 (enExample) |
| EP (2) | EP4089171A1 (enExample) |
| JP (1) | JP2024521063A (enExample) |
| CN (1) | CN117836420A (enExample) |
| AU (1) | AU2022273863A1 (enExample) |
| CA (1) | CA3219795A1 (enExample) |
| ES (1) | ES3073712T3 (enExample) |
| MX (1) | MX2023013385A (enExample) |
| WO (1) | WO2022238557A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12668817B1 (en) * | 2025-07-10 | 2026-06-30 | Telomere Therapeutics S.L. | Recombinant adeno-associated viral vectors for delivering a therapeutic gene to lungs |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| CA2188157A1 (en) * | 1994-05-18 | 1995-11-23 | Children's Hospital Medical Center | Nucleic acid sequences controlling lung cell-specific gene expression |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| EP1007637B1 (en) | 1997-04-14 | 2004-06-30 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant aav product |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| CN1247788C (zh) | 1997-05-13 | 2006-03-29 | 北卡罗来纳-查佩尔山大学 | 基于慢病毒的基因转移载体 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| DE19909769A1 (de) | 1999-03-05 | 2000-09-07 | Bundesrepublik Deutschland Let | Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen |
| AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| US20080188431A1 (en) * | 2004-09-08 | 2008-08-07 | Chiorini John A | Transcytosis of Adeno-Associated Viruses |
| ES2590461T3 (es) * | 2010-07-02 | 2016-11-22 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | La transcriptasa inversa de la telomerasa como protección frente al envejecimiento |
| US9453209B2 (en) * | 2012-12-27 | 2016-09-27 | Sierra Sciences, Llc | Enhancing health in mammals using telomerase reverse transcriptase gene therapy |
| ES2936383T3 (es) | 2014-08-08 | 2023-03-16 | Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio | Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio |
| EP3485914B1 (en) | 2014-08-08 | 2021-01-13 | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Telomerase reverse transcriptase-based therapies |
-
2021
- 2021-05-12 EP EP21382441.0A patent/EP4089171A1/en not_active Withdrawn
-
2022
- 2022-05-12 AU AU2022273863A patent/AU2022273863A1/en active Pending
- 2022-05-12 EP EP22729147.3A patent/EP4337780B1/en active Active
- 2022-05-12 MX MX2023013385A patent/MX2023013385A/es unknown
- 2022-05-12 JP JP2023570195A patent/JP2024521063A/ja active Pending
- 2022-05-12 ES ES22729147T patent/ES3073712T3/es active Active
- 2022-05-12 WO PCT/EP2022/062990 patent/WO2022238557A1/en not_active Ceased
- 2022-05-12 US US18/560,053 patent/US20250099618A1/en active Pending
- 2022-05-12 CN CN202280049735.6A patent/CN117836420A/zh active Pending
- 2022-05-12 CA CA3219795A patent/CA3219795A1/en active Pending
-
2025
- 2025-02-12 US US19/051,949 patent/US20260115322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20260115322A1 (en) | 2026-04-30 |
| WO2022238557A1 (en) | 2022-11-17 |
| ES3073712T3 (en) | 2026-07-14 |
| EP4337780A1 (en) | 2024-03-20 |
| AU2022273863A1 (en) | 2023-12-07 |
| US20250099618A1 (en) | 2025-03-27 |
| EP4337780B1 (en) | 2026-04-01 |
| CN117836420A (zh) | 2024-04-05 |
| EP4089171A1 (en) | 2022-11-16 |
| JP2024521063A (ja) | 2024-05-28 |
| EP4337780C0 (en) | 2026-04-01 |
| CA3219795A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019009525A2 (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este | |
| MX2015012739A (es) | Composiciones y metodos para tratar la mucopolisacaridosis tipo 1. | |
| CL2020002201A1 (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidación reducida de la cápside y usos de estos. | |
| EA201070184A1 (ru) | Бакуловирусные векторы, включающие повторные кодирующие последовательности с дифференциальными неоднозначностями кодонов | |
| MX2020008933A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| PE20181140A1 (es) | Adenovirus oncolitico que codifica una proteina b7 | |
| MX2016011585A (es) | Vectores aav mejorados adicionales producidos en celulas de insecto. | |
| PE20250258A1 (es) | Variantes de alfa-glucosidasa acida y usos de las mismas | |
| CL2016000502A1 (es) | Vectores mejorados del factor viii del virus adeno-asociado de menos de 5,0 kb de longitud, que producen un polipéptido del factor viii funcionalmente activo para el tratamiento de la hemofilia a. | |
| AR055128A1 (es) | Metodos y composiciones para la expresion de un polinucleotido de interes | |
| ECSP23072174A (es) | Composición y métodos para el tratamiento de la enfermedad de fabry | |
| AR123369A1 (es) | VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2 | |
| MX2022000038A (es) | Virus del dengue atenuados. | |
| DE602004011487D1 (de) | Modifizierter tert-promotor mit verbesserter tumorspezifität und stärke sowie diesen enthaltender rekombinanter vektor | |
| CL2024000481A1 (es) | Proteína de la cápside vp1 modificada aislada de aav9 | |
| AR125143A1 (es) | Terapias génicas para la deficiencia de la 21-hidroxilasa | |
| AR102234A1 (es) | Vector adenoviral que codifica atonal homólogo-1 humano (hath1) | |
| PE20240214A1 (es) | Nuevos anticuerpos anti-a2ap y usos de los mismos | |
| Hernández-Rodríguez et al. | Medium and large mammals in reduced-impact logging and conservation sites in Sierra Juárez, Oaxaca | |
| YADAV et al. | Effects of Scrap Rubber TYRE Aggregates as Partial Replacement of Natural Aggregates in High Strength Concrete | |
| AR126840A1 (es) | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta | |
| BARRERA et al. | Vertimiento de aguas residuales domiciliarias y el grado de contaminación del río Pisco, Ica | |
| КЕРИМ | Discussions of Gasprinsky with NP Ostroumov | |
| BR112021001582A2 (pt) | Heterorhabditis bacteriophora com tempo de vida ampliado | |
| Lolas Stepke | Die anthropologische Zukunft. Entwicklungslinien für die Medizin. |